Lv3
396 积分 2024-09-23 加入
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
19天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
19天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
19天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
2个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
2个月前
已完结
Metastatic Nasopharyngeal Carcinoma The JUPITER-02 Randomized Clinical Trial
4个月前
已完结
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial
7个月前
已完结
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial
7个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
8个月前
已完结
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
9个月前
已完结
皖公网安备34019202002308
